ALEVATE
LIVE

Serial Number

79350535

Owner

Albumedix Ltd

Attorney

Karen Lim

Filing Date

May 17, 2022

Add to watchlist:

No watchlists yet
View on USPTO

ALEVATE Trademark

Serial Number: 79350535 • Registration: 7582839

ALEVATE is a trademark filed by Albumedix Ltd on May 17, 2022. The trademark is classified under Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 45 (Legal & Security Services). The application is currently registered and active.

Owner Contact Info

Albumedix Ltd (16 trademarks)

HQ, Mabel Street

Entity Type: 99

Sartorius Albumedix Limited (8 trademarks)

HQ, Mabel Street

Entity Type: 98

Trademark Details

Filing Date

May 17, 2022

Registration Date

December 3, 2024

Published for Opposition

October 1, 2024

Goods & Services

Research and development services in the field of new biological, pharmaceutical, biopharmaceutical, chemical and medical products; technological consultancy, namely, providing consultancy and expert assistance in the field of new product development of medicines and pharmaceutical products, and laboratory analysis in the field of medicines and pharmaceuticals; research, development and laboratory analysis services relating to pharmaceutical and medicinal goods, in particular, albumin, chemicals, peptides, proteins, antibodies, cells, nucleic acids, viruses, live viruses, live-attenuated viruses, attenuated viruses, virus-like particles and viral vectors; quality management services, namely, quality evaluation and analysis, quality assurance, and quality control in the field of pharmaceutical, biopharmaceutical, chemical, and medical products; certification, namely, quality control services in the field of biological, pharmaceutical, biopharmaceutical, chemical, and medical products; certification, namely, quality assurance services in the field of biological, pharmaceutical, biopharmaceutical, chemical, and medical products; process monitoring, namely, quality assurance in the field of biological, pharmaceutical, biopharmaceutical, chemical, and medical products; quality control services for others in the field of development and testing of cells; services of a scientific chemical and biological laboratory; development and testing of chemical, pharmaceutical, biopharmaceutical, chemical, and medical production methods; quality control services for others and authentication services in the field of biological, pharmaceutical, biopharmaceutical, chemical, and medical products; process monitoring, namely, providing quality assurance services in the field of biological, pharmaceutical, biopharmaceutical, chemical, and medical products; scientific and medical laboratory services; information, consultancy and advisory services for research, testing, and development in the pharmaceutical, biopharmaceutical, chemical, and medical fields, none of the foregoing related to financial software

Regulatory compliance auditing; regulatory compliance consultancy in the field of biotechnology, pharmaceuticals, biopharmaceuticals, and medical testing and research; reviewing standards and practices to assure compliance with laws and regulations in the fields of biology, pharmaceuticals, biopharmaceuticals, chemicals, and medicine; information, consultancy and advisory services for the aforementioned services

Education, namely, classes, seminars, and workshops in the fields of biology, medicine, biologicals, biopharmaceuticals, pharmaceuticals, and chemical analysis; providing of training in the fields of biology, medicine, biologicals, biopharmaceuticals, pharmaceuticals, and chemical analysis; teaching and training in the fields of biology, medicine, biologicals, biopharmaceuticals, pharmaceuticals and chemical analysis; teaching and training in the fields of development and use of vaccines, growth factors, immune modulators, monoclonal antibodies, cells, cell therapies, tissues, proteins, recombinant proteins, nucleic acids, gene therapies, products derived from living culture systems, products derived from human blood, products derived from plasma; provision of medical, biological, biopharmaceutical, pharmaceutical and chemical instruction courses; organization of educational conferences in the fields of medical, biological, biopharmaceutical, pharmaceutical and chemical research and development; technical training in the field of medical, biological, biopharmaceutical, pharmaceutical and chemical analysis; information, consultancy and advisory services for the aforementioned services

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
May 31, 2025 FINO
GENERIC MADRID TRANSACTION SENT TO IB
Apr 25, 2025 XXSS
GENERIC MADRID TRANSACTION CREATED
Apr 25, 2025 XXCR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 16, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 16, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 16, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Apr 16, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Apr 16, 2025 COAR
CHANGE OF NAME/ADDRESS REC'D FROM IB
Apr 11, 2025 ADCH
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Mar 3, 2025 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Dec 3, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Dec 3, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 1, 2024 NPUB
PUBLISHED FOR OPPOSITION
Oct 1, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 11, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 28, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 24, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 24, 2024 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jun 24, 2024 ERFR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Mar 18, 2024 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 28, 2024 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Feb 28, 2024 OPNR
NOTIFICATION OF FINAL REFUSAL EMAILED
Dec 31, 2023 GNFN
FINAL REFUSAL E-MAILED
Dec 31, 2023 GNFR
FINAL REFUSAL WRITTEN
Dec 31, 2023 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 3, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 3, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 3, 2023 TROA
REFUSAL PROCESSED BY IB
May 24, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
May 4, 2023 RFCS
REFUSAL PROCESSED BY MPU
May 4, 2023 RFRR
NEW REPRESENTATIVE AT IB RECEIVED
Apr 2, 2023 NREP
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 16, 2023 RFCR
NON-FINAL ACTION WRITTEN
Mar 15, 2023 CNRT
ASSIGNED TO EXAMINER
Mar 7, 2023 DOCK
NEW REPRESENTATIVE AT IB RECEIVED
Jan 29, 2023 NREP
APPLICATION FILING RECEIPT MAILED
Sep 27, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 23, 2022 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Sep 22, 2022 REPR